EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Extracorporeal photopheresis for BK virus nephropathy as a novel treatment for high-risk rejection kidney transplant recipient

Marilena Gregorini, Claudia Del Fante, Tefik Islami, Maria Antonietta Grignano, Nicoletta Serpieri, Cesare Perotti, Gianluca Viarengo, Alessia Locurcio, Giuseppe Lanotte, Alessandro Tragni, Emma Diletta Stea, Chiara Martinelli und 7 weitere

Frontiers in Nephrology · 21.07.2025 · 5

DOI: 10.3389/fneph.2025.1625060 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Nephrology, online erschienen am 21.07.2025. Verfasst von Marilena Gregorini und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Nephrology, Dialysis and Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavi…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

BK virus-associated nephropathy (BKVAN) is a major complication in kidney transplantation caused by the reactivation of latent BK virus (BKV) under immunosuppression. BKVAN has been strongly associated with increased graft loss. Currently, there is no effective antiviral treatment for BKVAN. Additionally, the development of donor-specific antibodies (DSAs) and the risk of acute and chronic rejection complicate the reduction of immunosuppressive therapy (IS). This case report illustrates the management of BKVAN in a highly sensitized transplant recipient and explores the potential use of extracorporeal photopheresis (ECP) as an immunomodulatory tool. Case 44-year-old Caucasian woman with a history of failed prior transplant and multiple transfusions underwent a second kidney transplant. Due to a high panel-reactive antibody level, she received induction therapy with plasma exchange, thymoglobulin and steroids, followed by maintenance with tacrolimus, mycophenolate mofetil (MMF), and steroids. Initial graft function was good, and protocol biopsies showed no rejection. In year four, the patient developed an increasing BKV viremia (peak of 40,050 copies/mL) and MMF was reduced, which cleared BKV in six months. Two years later, DSAs reappeared, which led to an increase in MMF. In August 2020 the patient showed a decline of GFR, elevated BKV viremia (peak 162,000 copies/mL), and a graft biopsy was performed revealing BKVAN. IS was reduced (MMF was discontinued, and tacrolimus was tapered). After eight months, the viremia cleared up, but anti-DR53 DSAs (MFI 16000) levels increased significantly. As the patient was highly sensitized and had a thrombosis of arteriovenous fistula, mTOR inhibitors were not recommended. In order to modulate alloimmunity without further suppressing antiviral immunity, ECP was introduced. Over the next two years, the patient showed stable renal function (eGFR 30–40 mL/min), no recurrence of BKV viremia, and a gradual reduction in DSAs titers. No acute rejection episodes occurred.

Conclusions

In a highly sensitized patient with BKVAN and contraindications to standard therapies, ECP combined with a tailored immunosuppressive regimen proved effective in controlling viral replication, preserving graft function, and mitigating alloimmune risks. Considering the potential of ECP as an adjunctive therapy in complex BKVAN scenarios, further investigation is warranted.

Schlagwörter

Stichwörter der Autor:innen

BK virusBKVANECPantibody mediated rejectionhigh sensitizedkidney transplantation

Autor:innen und Institutionen

  • Unit of Nephrology, Dialysis and Transplantation, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
  • Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
  • Division of Immunohaematology and Transfusion Service, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.

Zitieren

APA

Gregorini, M., Del Fante, C., Islami, T., Grignano, M. A., Serpieri, N., Perotti, C., Viarengo, G., Locurcio, A., Lanotte, G., Tragni, A., Stea, E. D., Martinelli, C., Marchi, A., Portalupi, V., De Mauri, A., Margiotta, E., Pattonieri, E. F., Soccio, G., & Rampino, T. (2025). Case Report: Extracorporeal photopheresis for BK virus nephropathy as a novel treatment for high-risk rejection kidney transplant recipient. Frontiers in Nephrology, 5. https://doi.org/10.3389/fneph.2025.1625060

Vancouver

Gregorini M, Del Fante C, Islami T, Grignano MA, Serpieri N, Perotti C, et al. Case Report: Extracorporeal photopheresis for BK virus nephropathy as a novel treatment for high-risk rejection kidney transplant recipient. Frontiers in Nephrology. 2025;5. doi:10.3389/fneph.2025.1625060

BibTeX
@article{Gregorini2025,
  author = {Gregorini, Marilena and Del Fante, Claudia and Islami, Tefik and Grignano, Maria Antonietta and Serpieri, Nicoletta and Perotti, Cesare and Viarengo, Gianluca and Locurcio, Alessia and Lanotte, Giuseppe and Tragni, Alessandro and Stea, Emma Diletta and Martinelli, Chiara and Marchi, Alessandro and Portalupi, Valentina and De Mauri, Andreana and Margiotta, Elisabetta and Pattonieri, Eleonora Francesca and Soccio, Grazia and Rampino, Teresa},
  title = {Case Report: Extracorporeal photopheresis for BK virus nephropathy as a novel treatment for high-risk rejection kidney transplant recipient},
  journal = {Frontiers in Nephrology},
  year = {2025},
  volume = {5},
  doi = {10.3389/fneph.2025.1625060}
}
Kostenlos starten →